J&J’s EPO Franchise Takes A Hit From Regulatory Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of the erythropoiesis-stimulating agent Procrit plunged 14 percent in the second quarter, causing J&J to revise sales expectations.